CAMBRIDGE, MA, Korro Bio, an RNA editing company, announced the completion of a $116M Series B financing led by Eventide Asset Management.
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, announced the completion of a $116M Series B financing.
The financing was led by Eventide Asset Management, with participation from new investors Fidelity Management & Research Company LLC, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an additional healthcare specialist fund. All existing investors participated in the financing, including Atlas Venture, NEA, Wu Capital, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about